Course Experts: Mishra, PharmD and Patrick McBride, PharmD, BCOP

Course Description: This course describes the mechanism of action and efficacy of asparaginase in targeting acute lymphoblastic leukemia (ALL) cell. It identifies asparaginase adverse effects and enables learners to design a safe and effective treatment plan for patients with ALL.

[DFCI_KEYWORDS] Chronic Lymphocytic Leukemia (CLL), Bruton’s Tyrosine Kinase (BTK) Inhibitors, Pathophysiology, Prognostic Markers, Genetic Markers, Cytogenetics, Ibrutinib, Acalabrutinib, Zanubrutinib, Pirtobrutinib, Lymphocytes, Lymphadenopathy, Venetoclax, Obinutuzumab, Rituximab, Fludarabine, Bendamustine, Antiplatelet, Anticoagulation, Leukocytosis